Pharmacogenomic Evaluation of Antihypertensive Responses 2

Location:

Rochester, Minn.

Trial status:
Open for Enrollment
Why is this study being done?

The proposed work should help move toward the long-term goal of selection of antihypertensive drug therapy based on a patient's genetic make-up. Hypertension (HTN) is the most common chronic disease for which drugs are prescribed, and the most prevalent risk factor for heart attack, stroke, renal failure and heart failure. Responses to antihypertensive drug therapy exhibit considerable interpatient variability, contributing to poor rates of HTN control (currently about 40-50% in the US), and frequent nonadherence and dropout from therapy. We propose to identify genetic predictors of the antihypertensive and adverse metabolic responses to two preferred and pharmacodynamically contrasting drugs, a beta-blocker (metoprolol) and a thiazide diuretic (chlorthalidone) in a sequential monotherapy design in 400 hypertensive individuals. Data collected will include home and clinic blood pressure, blood samples for testing for adverse metabolic effects and other biomarkers, RNA, and DNA and urine sample. We will conduct genome-wide association SNP genotyping and data from the study will be used for replication of findings from the previous PEAR trial, along with new discoveries. The primary aims are to define the genetic determinants of the antihypertensive response and adverse metabolic responses (e.g. changes in glucose, triglycerides and uric acid). The proposed research is significant because genetically-targeted antihypertensive therapy could lead to dramatically higher response rates and fewer adverse effects than the usual trial-and-error approach. This would likely lead to higher rates of HTN control, less need for polypharmacy, reduced health care costs, and improved outcomes.

Who is eligible to participate?

Inclusion Criteria: - An average seated home DBP > 85 mmHg and < 110 mmHg and home SBP < 180 mmHg. - Subjects must also have an average seated (> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP < 180 mmHg Exclusion Criteria: - Secondary forms of HTN (including sleep apnea) - Isolated systolic HTN - Other diseases requiring treatment with BP lowering medications - Heart rate < 55 beats/min (for metoprolol only) - Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA) - Diabetes mellitus (Type 1 or 2) - Renal insufficiency (serum creatinine > 1.5 in men or 1.4 in women) - Primary renal disease - Pregnancy or lactation - Liver enzymes > 2.5 upper limits of normal - Current treatment with NSAIDS, COX2-inhibitors, oral contraceptives or estrogen.

Karen S. Miller
Associate Clinical Research Coordinator
Division of Nephrology and Hypertension Research

Last updated:
5/20/2013
NCT ID:
NCT01203852